We have resolved multiple forms of cyclic nucleotide phosphodiesterase (PDE) in whole rat ventricle and in isolated rat ventricular myocytes by use of anion-exchange high-performance liquid chromatography. One major form, the soluble calmodulin-stimulated PDE, is apparently absent from isolated myocytes. We discern four peaks of PDE activity (designated A-D in the order of their elution) in a soluble fraction obtained from whole rat ventricle. Peak A is stimulated twofold to threefold by the addition of calcium and calmodulin (Ca2'/CalM) and preferentially hydrolyzes cGMP over cAMP (in the presence of Ca2'/CalM, KmCGMP= 1.5 ,uM, KmC`mP=17 ,M). Peak B has similar affinities for both cAMP and cGMP (half-maximum velocities achieved at 30 ,M substrate) and demonstrates positive cooperativity with cAMP but not with cGMP. The hydrolysis of cAMP by peak B is stimulated by cGMP at substrate concentrations up to 20 ,uM; the maximum effect is seen at 1 ,uM cAMP (25-fold stimulation by 3 ,uM cGMP). This pattern of stimulation by cGMP results from two kinetic changes: an increase in the enzyme's apparent affinity for cAMP (apparent KmCJMP decreases from 33 to 11 ,uM) and the abolition of positive cooperativity. Peaks C and D selectively hydrolyze cAMP, are not stimulated by Ca2+/CalM or cGMP, and differ in their affinities for substrate (peak C, apparent KmC.IP=7.2 ,uM; peak D, 0.44 ,uM). In addition, peak D is much more sensitive than peak C to inhibition by cGMP, cilostamide, rolipram, and milrinone. Ro20-1724 is a slightly more potent inhibitor of peak D than of peak C. Peak D appears to consist of two different enzyme activities, one inhibited by cGMP, cilostamide, and cardiotonic drugs and the other potently inhibited by rolipram. In contrast to whole ventricle, the soluble fraction of isolated rat ventricular myocytes lacks peak A. Three major peaks in myocytes are entirely analogous to peaks B, C, and D of whole ventricle in terms of the NaCl concentration at which they elute, substrate affinities, and stimulation or inhibition by various drugs and effectors. We conclude that the soluble Ca2'/CalM-stimulated PDE in whole rat ventricle is present in nonmyocyte cells. (Circulation Research 1991;68:1070-1079) C yclic nucleotide phosphodiesterase (PDE; EC 3.1.4.17) catalyzes the hydrolysis of cAMP and cGMP to the corresponding 5'-nucleosides.' Most tissues contain multiple isozymes of cyclic nucleotide PDE, the forms differing in their kinetic properties (substrate preference, affinity, and sensitivity to competitive inhibitors) and modes of regulation (mainly by cGMP and calcium and calmodulin [Ca2+/ CalM]).2 We became interested in the PDE activities in cardiac tissue after we found that a1-adrenergic stimulation enhances the breakdown of cAMP in rat ventricular myocytes.3 PDE activity is regulated by hormones in other tissues: insulin stimulates PDE activity in adipocytes4 and hepatocytes,5 and muscarinic cholinergic agonists stimulate a Ca2'/CalM-sensitive PDE in cultured human astrocytoma cells6 and in dog thyroid.7 Because a1-adrenergic receptors in rat myocytes couple to phosphoinositide metabolism, we hypothesized that a-adrenergic stimulation might, by a mechanism involving inositol trisphosphate-mediated Ca2' release, cause activation of a Ca2'/CalMsensitive PDE in myocytes. During the testing of this hypothesis, we have characterized the isoforms of PDE in soluble fractions from rat ventricle and purified ventricular myocytes.
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Since 1971, the standard method for resolving multiple forms of PDE from a tissue has been chromatography on an open column of DEAE-cellulose, eluting with a sodium acetate gradient.8 This procedure resolves three peaks of activity from cardiac tissue of various species. 8.9 Recently, four peaks of PDE activity have been identified by open-column chromatography on DEAE-Sephacel10 or DEAE-Sepharose.1" Working with small quantities of purified myocytes, we found that traditional methods failed to provide a rapid separation with satisfactory resolution. Therefore, we developed a high-performance liquid chromatographic (HPLC) separation by use of a quaternary amine ion-exchange column (Pharmacia's Mono Q column).12 With this procedure, we achieve excellent separation of PDE activities from as little as 200 ,gg of myocyte protein. With the HPLC procedure, we resolve four peaks of PDE activity in the soluble fraction from rat ventricle but only three from purified ventricular myocytes. The data presented here demonstrate that the soluble Ca2'/CalM-sensitive form of PDE found in rat heart is absent from the soluble fraction of rat ventricular myocytes and is most likely contributed by nonmyocyte elements such as the vasculature. In addition, we present data on some characteristics of each of the peaks of cardiac PDE activity.
Materials and Methods Tissue Preparation
Hearts were excised from adult male Sprague-Dawley rats (250-300 g body weight) that were previously heparinized (1,500 units/kg) and anesthetized with 40 mg/kg pentobarbital. Whole ventricular tissue was prepared by flushing the hearts with physiological saline through the aorta to free them of blood, after which the aorta and great vessels were trimmed off and the ventricles frozen with Wollenberger clamps. 13 The frozen tissue was pulverized in a percussion mortar cooled in liquid nitrogen; the powdered tissue was stored at -70°C. Ventricular myocytes were isolated and purified by perfusion of rat hearts with collagenase, following the method described by Buxton and Brunton.14 For enzyme assay and chromatography, frozen tissue powder was homogenized in a Duall groundglass homogenizer (Kontes, Vineland, N.J.) in approximately 10 volumes of cold (4°C) homogenizing buffer (25 mM Bis-Tris HCI [(bis-[2-hydroxyethyl]imino)tris-(hydroxymethyl)-methane HCl], pH 6.5, 5 mM MgCl2, 4 mM 2-mercaptoethanol, 0.5 mM EGTA, 0.1 mM PMSF [phenylmethylsulfonyl fluoride], and 10 gg/ml leupeptin). The homogenate was centrifuged at 3,000g for 5 minutes, and the resulting supernatant was called the "soluble fraction," consistent with the distribution of other enzymes that we have localized to soluble and particulate fractions of cardiac tissue.14 Before injection onto the HPLC column, the supernatant was filtered through a 0.22-,tm syringe filter.
HPLC Resolution of PDE Isozymes
The soluble fraction from whole rat ventricle or rat ventricular myocytes (0.25-4 mg protein in 0.25-1.0 ml) was loaded onto a Mono Q HPLC column (5 x 0.5 cm; bed volume, 1.0 ml), and the proteins were eluted with a linear gradient of NaCl from 75 mM to 500 mM (in 25 mM Bis-Tris, pH 6.5) at a flow rate of 1 ml/min. The total volume of the gradient was 28 ml. Fractions of 0.4 ml were collected, of which 25 ,ul was assayed for PDE activity. The total run time was 32 minutes, and the separation was conducted at room temperature. This method is described in detail in Reference 12.
Assay of PDE Activity
PDE activity in the soluble fraction was assayed by the two-step method of Thompson 
Results
The HPLC method clearly resolves four peaks of PDE activity from a soluble fraction of whole rat ventricle ( Figures 1A and 1B ). The peaks are designated A-D in the order of their elution by a NaCl gradient. Figure 1A demonstrates one way of visualizing the peaks (i.e., the fractions in the first two peaks were assayed with 1 ,uM cGMP as substrate and those in the last two peaks with 1 ,uM cAMP as substrate). Calcium (approximately 1 mM free) and calmodulin (1 ,M) were present in all assays. Another way of detecting the four peaks is to assay with 1 ,uM cAMP as substrate in all fractions, as shown in Figure 1B . Under these conditions, calcium and calmodulin are added to visualize peak A, and the addition of cGMP activates peak B, permitting its localization; no additions are required to see peaks C and D.
To determine their kinetic characteristics (i.e., Vm., and apparent K,) the fractions corresponding to each peak were pooled and assayed with different concentrations of the substrates cAMP and cGMP, ranging from 0.01 to 100 ,M. The results are summarized in Table 1 . Lineweaver-Burk plots (not shown) were linear for all peaks under all conditions except where positive cooperativity was evident (i.e., peak B with cAMP as substrate in the absence of cGMP). Peak A has a higher affinity for cGMP (apparent Km= 1.5 ,uM in the presence of Ca2'/CalM) than for cAMP (17 ,iM) and is stimulated considerably by Ca2'/CalM; the affinity for either substrate is slightly higher in the presence of Ca2'/CalM, and the Vm,,, increases 2.5-fold to threefold. Thus, peak A is the calmodulin-stimulated PDE. Peak B is the cGMP-stimulated PDE; with 1 1,M cAMP as substrate, the activity is stimulated 25-fold by the addition of 3 ,uM cGMP. The stimulation results from an increase in affinity for cAMP and loss of the positive cooperativity that is seen with cAMP as substrate in the absence of cGMP (see footnote, Table 1 ). The enzyme has the same affinity for either substrate (apparent Kin, 33 ,uM for cAMP in the absence of cGMP versus 29 ,M for cGMP). The addition of Ca2+/CalM modestly stimulates the activity of this enzyme by slightly increasing the affinity for either substrate but has no effect on the Vm.. Peaks C and D are both selective for cAMP as substrate and do not measurably hydrolyze cGMP. Neither peak is stimulated by Ca2+/CalM or cGMP; indeed, cGMP inhibits peak D (see text below, Table 2 , and Figure  6 ). Peak C has a moderately high affinity for cAMP (apparent Km, 7.2 ,uM), and the affinity of peak D for cAMP is higher than that of any of the other forms (apparent Km, 0.44 ,uM).
When we looked at the profile of PDE isozymes in the soluble fraction from purified rat ventricular myocytes, we found that peak A was essentially absent (Figure 2 ). This figure should be compared with Figure 1A , in which fractions eluted from the soluble portion of whole ventricle were assayed under the same conditions as the fractions from isolated myocytes shown in Figure 2 . (Peak A is not very prominent in the activity profile of whole ventricle shown in Figure 1B because these assays used cAMP as substrate, whereas the velocity of cGMP hydrolysis by peak A is greater [see Table 1 ].) The same result was obtained when the soluble fraction obtained from whole ventricle or isolated myocytes was ana-z t- lyzed by open-column DEAE chromatography (data not shown). The lack of peak A in myocytes is reflected in the relative amounts of cGMP-hydrolyzing PDE activity in the crude, unfractionated soluble fraction obtained from myocytes compared with that obtained from whole ventricle. In a representative experiment, the total cGMP-PDE activity in the crude myocyte soluble fraction was 31% of the cAMP-PDE activity compared with 113% in the whole ventricle. The total cGMP-PDE activity in the crude myocyte soluble fraction (expressed per milligram of total protein) was approximately 32% of the total cGMP-PDE activity in the ventricle, reflecting the nearly total loss of peak A and comparable activity of peak B. The small amount of activity in myocytes that appears in fractions corresponding to peak A (approximately 6% of the activity in whole ventricle, Figure 1A ) correlates exactly with the low level of contamination of myocytes with other cell types (5-10%).14 Peaks B, C, and D from myocytes are apparently identical to the corresponding peaks from whole ventricle with respect to the NaCl concentration at which they elute (compare Figures 1A and 2 ), their affinities for the substrates cAMP and cGMP, and stimulation by cGMP (peak B) or Ca2'/CalM (slight effect on the affinity of peak B). In addition, there apparently are activities hydrolyzing cAMP in fractions eluted from isolated myocytes that do not correspond to any of the four peaks eluted from whole ventricle (i.e., immediately preceding peak B and between peaks C and D). We investigated the possibility that the lack of peak A in purified myocytes was an artifact of the isolation procedure. For instance, perhaps peak A is proteolyzed or otherwise damaged during perfusion of the heart with collagenase or during the subsequent myocyte purification. With this in mind, we looked at the HPLC profile of PDE activity in the 3 . Resolution ofphosphodiesterase activities from collagenase-treated, unpurified ventricle. Our standard collagenase perfusion proto-col14 was followed through the teasing apart of ventricular tissue in collagenase solution but without removal ofdebris orpurification ofcell types. From a frozen pellet of this tissue suspension (obtained by centrifugation at SOgfor 2 minutes), a soluble fraction was made. Chromatography was performed as previously described (with 0.22 mg protein in 0.25 ml), except that the gradient varied from 0 to 0.5 M NaCl in 24 minutes. soluble fraction from whole rat ventricular tissue that was exposed to collagenase at 32°C for the same length of time as the purified myocytes during their isolation (Figure 3 ). Peak A is present in this treated tissue, demonstrating that the lack of peak A in myocytes is not due to its degradation by collagenase. We also looked at two tissue fractions that are normally discarded in the course of purifying myocytes because they are enriched in nonmyocyte cells. One consists of material that does not pass through a nylon mesh after collagenase treatment. The other fraction contains cells (including nonmyocyte cell types and dead myocytes) that remain in suspension and do not settle during the final stages of myocyte purification. Peak A was present in each of these fractions. (The data [not shown] are essentially the same as those presented in Figure 3 .) Furthermore, the inclusion of the protease inhibitors leupeptin and PMSF (present in the homogenization buffer) in the chromatography buffer had no effect on the profile of PDE activities resolved from isolated myocytes (data not shown).
It seemed possible that the stability of the activity of peak A might differ between homogenates of whole ventricle and purified ventricular myocytes. Such a differential stability could lead to differing 25- chromatographic properties of peak A in the two homogenates or possibly to the degradation of peak A, thereby accounting for the absence of peak A in homogenates of purified myocytes. However, we find that peak A is quite stable in myocyte homogenates (Figure 4 ). When bona fide peak A (resolved from whole ventricle) was added to the soluble fraction of purified myocytes and the mixture was chromatographed over the HPLC anion exchange system, peak A was quantitatively recovered, eluting with the same retention time (same [NaCI]). Thus, we conclude that the lack of peak A after chromatographic resolution of the soluble fraction of purified myocyte reflects the absence of the Ca2'/CalM-stimulated PDE activity from myocytes rather than a procedural artifact.
Peaks C and D are characterized by their differential susceptibilities to a variety of isozyme-selective inhibitors. Rather than use the same concentration of cAMP as substrate for both peaks, we used a concentration near the apparent Km for each peak (10 ,uM for peak C, 0.4 ,uM for peak D) in studying the susceptibility of these activities to inhibitors. Figure 5 shows concentration dependence curves for several compounds on peak C from myocytes; the results with peak C from whole ventricle were essentially the same. The slight stimula- FIGURE 4 . Phosphodiesterase activities in soluble fraction from purified myocytes mixed with ventricular peak A. A soluble fraction ofpurified ventricular myocytes (2.5 mg protein/ml) was mixed 1:1 with pooled peak A obtained by chromatography of the soluble fraction of whole rat ventricle. The mixture (1.0 ml) was chromatographed as previously described, except that the salt gradient was 125 -450 mMNaCl in 28 minutes. z t--FIGURE 5. Susceptibility of myocyte peak C to inhibition. Peak C (comparable to fractions 49-52, Figure 2 ) was pooled and characterized with respect to substrate preference and modulator requirements (see Table 1 ). For these experiments, the substrate (cAMP) was used at 10 M, which is near the apparent Km for this enzyme peak. Reactions (200 d) contained the indicated inhibitors and were initiated by the addition of 25 pd ofpeak C protein. Data are from a single representative experiment.
tion at high cGMP concentrations may reflect a low level of contamination of peak C with peak B. The extent of contamination is extremely small: 25% stimulation as shown in Figure 5 compared with 500% stimulation of peak B by 3 gM cGMP at a cAMP concentration of 10 ,uM (data not shown). The rank order of potency of inhibitors of peak C was rolipram> Ro20-1724>milrinone> > >cilostamide and cGMP (little or no inhibition). In contrast, peak D shows a different rank order of potency: cGMP=cilostamide> rolipram>milrinone>Ro20-1724 ( Figure 6 ). Note that the inhibition of peak D by cGMP, cilostamide, rolipram, and Ro20-1724 was incomplete: 33-60% of the original activity remained in the presence of the highest concentration of each compound. Dixon plots (not shown) were largely linear for cGMP, cilostamide, and rolipram but not for milrinone and Ro20-1724. Rechromatography of peak D on the Mono Q column with a shallower salt gradient (300-450 mM NaCl in 28 minutes compared with the usual gradient of 75-500 mM NaCl in 28 minutes) did not provide conclusive evidence for a second peak within peak D (data not shown). The results obtained after rechromatography of peak D on a gel filtration HPLC column (Spherogel-TSK 3000-SW column [Beckman Instruments, Inc., Fullerton, Calif.], eluting with 100 mM NaCl in 25 mM Bis-Tris; pH 6.5) suggested the presence of PDE activities with two different apparent molecular weights. However, both activities were inhibited to the same extent (approximately 75%) by 20 ,uM rolipram (data not shown). Thus, the incomplete inhibition of peak D by cGMP, cilostamide, rolipram, and Ro20-1724 is not readily explained by the presence of sensitive and insensitive forms of PDE that are readily separable on the basis of differences in charge or molecular weight. Figure 7 provides pharmacological evidence for the existence of multiple PDE isozymes within peak D. In this representative experiment, increasing concentrations of cilostamide alone inhibited about one third of the activity in peak D, with an IC50 of 4.2 x 108 M. Rolipram (30 ,uM) inhibited two thirds of the activity, and the addition of cilostamide resulted in the inhibition of the remaining activity, with an IC50 of 4.9x M. The results of the converse experiment (not shown), in which increasing concentrations of rolipram were used in the absence and presence of 2 ,uM cilostamide or 5 ,uM cGMP, were consistent with the results shown in Figure 7 . In addition, cGMP had no effect on the peak D activity remaining in the presence of 2 ,uM cilostamide (data not shown). FIGURE 6. Susceptibility of myocyte peak D to inhibition. Peak D (comparable to fractions 59-63, Figure  2 ) was pooled and characterized (see Table 1 ). For these experiments, cAMP was used at 0.4 1M, which is near the apparent Kn of this activity. Other details are similar to those described for Figure 5 . Maximally effective concentrations of cGMP, cilostamide, and rolipram produced only partial inhibition. The data on the effects of several inhibitors are summarized in Table 2 . Because substrate concentration was near the apparent Km for each peak (10 ,uM for peak C, 0.4 ,uM for peak D), the concentrations of a compound that inhibit 50% of the inhibitable activity (150) of the two peaks can be compared directly. The results obtained with whole ventricle were very similar (data not shown), confirming the correspondence of peaks C and D in whole ventricle and purified myocytes.
Discussion
We report here the first evidence that the calmodulin-stimulated PDE is not present in a soluble *150 values were calculated by nonlinear regression analysis of inhibition curves such as those shown in Figures 5 and 6 with the computer program INPLOT (GraphPAD Software). We define the 150 as the concentration of a compound that inhibits 50% of the inhibitable activity. This is in contrast to the IC50 value that generally refers to the concentration required to inhibit 50% of the total activity. In the case where the activity of a pure enzyme is being measured, 150=1C50. However, in the case of a compound that is a selective inhibitor of one of the multiple isozymes present in an assay, the 150 is significantly lower than the IC50. For example, in Figure 6 cGMP inhibits less than 50% of the total activity in peak D; thus, the apparent IC50 would be -10 ,uM. However, the cGMP inhibitory component is quite sensitive to cGMP (150=0.11 ,uM). We chose to express the inhibition data in terms of ISO values because they provide more information about the inhibitor-sensitive component of the enzyme activity in those cases where multiple isozymes are apparently present. Because the substrate concentration for each peak was near the apparent Km for that peak, the 1So values for peaks C and D can be compared directly.
As noted in the Table 1 legend, peak D is heterogeneous, as evidenced by the patterns of partial and differential inhibition by cGMP, cilostamide, and rolipram (see Figure 7 ). fraction of ventricular myocytes purified from adult rat heart. Its apparent absence is not an artifact of the myocyte purification; the activity is not destroyed by the process of purification, is present in tissue fractions that are enriched in nonmyocyte cells, but is practically undetectable in purified myocytes. The small amount of Ca2'/CalM-stimulated PDE activity in myocyte extracts (Figure 2 ) that appears in fractions corresponding to peak A (approximately 6% of the activity in whole ventricle [ Figure 1A ]) is equivalent to the low level of contamination of the isolated myocyte preparation with other cell types (5-10%)14 that do contain this form of PDE.
Several other observations argue against the possibility that the apparent absence of the Ca2+/CalMstimulated PDE activity in myocytes is merely an artifact of proteolytic degradation. First, peak A is still evident in whole ventricular tissue after exposure to collagenase at 32°C for the same length of time as myocytes during their isolation. Furthermore, addition of the protease inhibitors leupeptin and PMSF to the chromatography buffer did not render peak A detectable in soluble extracts of myocytes. Finally, peak A from whole ventricle preferentially hydrolyzes cGMP, and no new peaks of activity that hydrolyze cGMP are evident in extracts of myocytes. Although proteolysis has been reported to activate the calmodulin-stimulated PDE and render it unresponsive to further stimulation by calmodulin,16 proteolysis would not be expected to alter substrate preference of the enzyme. The possibility of some kind of artifact peculiar to isolated myocytes, which would result from either proteolysis or some other phenomenon, was ruled out by the elution of ventricular peak A in the presence of the soluble fraction from myocytes. Although we consider it unlikely, we cannot rule out the possibility that our purification protocol removes a subpopulation of myocytes that happen to contain peak A.
The peaks of PDE activity that we resolve by HPLC are far from homogeneous; silver-stained SDS-polyacrylamide gels reveal the presence of multiple protein bands within each peak (data not shown). However, the different isoforms of PDE are sufficiently well resolved, so that each peak is readily distinguishable from the others in terms of substrate preference and affinity and sensitivity to modulators and inhibitors. The profile of PDE activities of isolated myocytes seems more complex than the profile obtained with whole ventricle. Especially evident (Figure 2 ) are the activities in fractions immediately preceding peak B (fractions 36-40) and between peak C (which is much less prominent in myocytes than in ventricle) and peak D (fractions 53-56). It is possible that these additional peaks noted in the soluble fraction from purified myocytes represent forms of PDE unnoticed in other preparations of cardiac tissue. Myocytes may represent as little as 12% of the cells in ventricle.17 Thus, an enzyme activity confined to myocytes and not detected in homogenates of ventricle may be enriched up to eightfold in purified myocytes and, viewed against a different background of activity, may become detectable. It is also possible that the additional fractions with PDE activity result from the action of endogenous proteolytic enzymes or collagenase during the myocyte preparation, although the protease inhibitors leupeptin and PMSF are present in the homogenization buffer.
In terms of the criteria listed by Beavo and Reif-snyder18 in their recent review of PDE isozymes and selective PDE inhibitors, the PDE isozymes that we have identified in the soluble fraction of rat ventricle and myocytes fall into the following categories: 1) peak A contains a Ca2+/CalM-stimulated activity, or PDE I; 2) peak B contains a cGMP-stimulated PDE or PDE II; 3) the cGMP-(and cardiotonic-) inhibited isozyme, PDE III, is found in peak D, which also contains a cGMP-insensitive, cAMP-specific activity (a member of the PDE IV family); 4) on the basis of substrate and inhibitor specificity, peak C appears to contain a PDE IV activity, albeit one that exhibits a lower affinity for substrate than that under peak D.
In some tissues, a high-affinity cGMP-specific, calmodulin-independent isozyme (PDE V) coelutes with PDE I on anion-exchange chromatography. The two forms can be separated by affinity chromatography on calmodulin-Sepharose; indeed, this methodology has been used to demonstrate the presence of both PDE I and PDE V in the soluble fraction of rat ventricle (E.D. Paqaui and P.J. Silver, personal communication). In a preliminary experiment, we have examined peak A from rat ventricle for PDE V activity. When assayed in the absence of Ca2+/CalM, with cGMP (2 ,uM) as a substrate, the activity of ventricular peak A can be inhibited by 33% with 1 ,uM Zaprinast (M&B22948, a relatively selective inhibitor of PDE V18), a concentration that is ineffective against the activity of peak B. This Zaprinast-sensitive activity may be PDE V, and PDE V may also be lacking in myo-attempts to resolve peak A into PDE I and PDE V, which will involve assaying relatively low activities and accounting for the contributions of nonmyocyte elements.
We initially engaged in these studies for the purpose of determining which PDE isozyme was stimulated by a,-adrenergic agonists in isolated rat ventricular myocytes.3 The isozyme and the mechanism by which it is activated remain undetermined, but we have ruled out the involvement of one form (i.e., a soluble calmodulin-stimulated PDE), as this form is apparently not present in these cells. This result is interesting and somewhat surprising because this isoform of PDE is activated by muscarinic agonists in dog thyroid7 and in 1321N1 human astrocytoma cells.6 This activation mechanism presumably involves elevation of the cytosolic free calcium concentration, which in turn promotes the interaction of calmodulin with the sensitive PDE, leading to its activation. In isolated rat myocytes, a,-adrenergic receptors are linked to phosphoinositide hydrolysis,19 just as muscarinic receptors are linked to phosphoinositide hydrolysis in many cell types.20 Thus, we had hypothesized that a soluble, calmodulin-stimulated PDE would be activated by a-agonists in rat myocytes, and we are continuing to pursue this question. One possibility is that a particulate rather than a soluble PDE is involved. The profile of PDE isozymes in the particulate fraction of rat ventricular myocytes has not yet been determined but should be amenable to investigation by the same HPLC methodology that we have used in studying the soluble PDEs. Of course, one can imagine other means by which a,-adrenergic stimulation could stimulate PDE activities; putative effectors include cGMP (acting to stimulate peak B activity) and a variety of protein kinases.
We had predicted that Ro20-1724 and rolipram might be selective inhibitors of peak C. This prediction was based on the findings of Reeves et al"l and Weishaar et al. 9 Reeves et al reported that both compounds inhibit a fairly high-affinity (Ki,, 2 ,uM for cAMP), cAMP-preferring PDE from a soluble fraction of human or guinea pig ventricle, with Ki values of 2-3 ,uM. Another PDE isoform with a higher affinity for substrate (Km, 0.14 ,uM for cAMP) was weakly inhibited (Ki>25 ,uM) by both compounds. This high-affinity form of PDE was potently and selectively inhibited by the drug SK&F 94120, which is reportedly similar in selectivity to milrinone and other cardiotonic agents though to act by inhibition of PDE activity. Weishaar et al characterized soluble and particulate PDE isoforms in canine and guinea pig ventricle. In canine ventricle, a calmodulin-insensitive, cAMP-specific PDE was present in both the soluble and particulate fractions; the particulate form was potently inhibited by cGMP and cilostamide and only weakly by Ro20-1724 and rolipram. Conversely, the soluble form was potently inhibited by Ro20-1724 and cytes. Clarification of this matter must await careful rolipram but weakly by cGMP and cilostamide.
These results suggested to us that Ro20-1724 and rolipram might be selective inhibitors of our peak C (a cGMP-and calmodulin-insensitive, cAMP-specific PDE that is not inhibited by cilostamide or cGMP) from the soluble fractions of rat ventricle and isolated rat myocytes. We found that Ro20-1724 and rolipram are indeed fairly potent inhibitors of peak C; however, rolipram is an even more potent inhibitor of peak D, and Ro20-1724 is slightly selective for peak D as well. The affinities of the two drugs for peak C are nearly identical to the Ki values reported by Reeves for the more sensitive isoform in human ventricle. Unexpectedly, the affinities of rolipram and Ro20-1724 for peak D are even higher, but only about 65% of the activity is inhibitable.
The incomplete inhibition of peak D by cGMP, cilostamide, rolipram, and Ro20-1724 suggests the possibility that peak D may be heterogeneous, perhaps containing inhibitor-sensitive and -insensitive forms of PDE. Rechromatography of peak D by gel filtration did provide evidence of more than one peak of activity; however, the extent of inhibition by 20 ,uM rolipram was approximately the same in all fractions. Dose-response curves for cilostamide in the absence and presence of rolipram provide conclusive evidence of more than one PDE isoform within peak D. Additionally, cGMP and cilostamide appear to inhibit the same isoform within peak D. Thus, the cGMP-(or cardiotonic-) sensitive PDE and the rolipram-sensitive PDE are both present in the soluble fraction of isolated rat myocytes, and both elute in our peak D. The rolipram-sensitive form is dominant, constituting about two thirds of the activity. Kariya and Dage21 have also separated the soluble, high-affinity cAMP PDE from rat heart into distinct cGMPand rolipram-inhibited subtypes, the latter accounting for the bulk of the activity. The fact that Dixon plots of our data on cGMP, cilostamide, and rolipram were largely linear suggests that each of these compounds is highly selective for one of the subtypes, as opposed to milrinone and Ro20-1724, which are less selective and have nonlinear Dixon plots (data not shown).
In addition to aiding our studies of the regulation of PDE activity by a1-adrenergic stimulation, the demonstration that rat ventricular myocytes do not contain a soluble calmodulin-stimulated PDE (whereas tissue fractions that are enriched in nonmyocyte cardiac cell types do contain this form) could have important clinical implications should a distinct cellular distribution of isozymes occur in humans as well. In the last few years, a new generation of cardiotonic drugs has been developed that share the property of being selective inhibitors of a high-affinity, cAMP-specific PDE. 22 The positive inotropic activity of these drugs results largely from the fact that their target enzyme is present in ventricular myocytes. For example, drugs that selectively block the calmodulin-stimulated PDE suggest that that isozyme of PDE is apparently localized to nonmyocyte cells in cardiac tissue.
Perhaps the Ca2'/CalM-stimulated PDE activity is abundant in vascular smooth muscle. If such were the case, a selective inhibitor of that isozyme might facilitate relaxation of vascular smooth muscle, thereby reducing blood pressure. Such a drug could be a useful antihypertensive agent because it would not produce unwanted stimulation of contractility in the ventricular myocytes, where the target enzyme is absent.
